Back
Yubo International Biotech 10K Form
Sell
24
YBGJ
Yubo International Biotech
Last Price:
$0.0461
Seasonality Move:
1070.83%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2021-05-24 | 10Q | YBGJ/Yubo International Biotech Quarterly |
2021-04-23 | 10K | YBGJ/Yubo International Biotech Annual |
2021-01-19 | 10Q | YBGJ/Yubo International Biotech Quarterly |
2020-10-20 | 10Q | YBGJ/Yubo International Biotech Quarterly |
2020-07-20 | 10Q | YBGJ/Yubo International Biotech Quarterly |
2020-06-25 | 10K | YBGJ/Yubo International Biotech Annual |
Receive YBGJ News And Ratings
See the #1 stock for the next 7 days that we like better than YBGJ
YBGJ Financial Statistics
Sales & Book Value
Annual Sales: | $604.7K |
---|---|
Cash Flow: | $-92.6K |
Price / Cash Flow: | 0 |
Annual Sales: | $-0.03 |
Price / Book: | 0 |
Profitability
EPS (TTM): | -0.01780 |
---|---|
Net Income (TTM): | $-2M |
Gross Margin: | $419.2K |
Return on Equity: | 0% |
Return on Assets: | -70.03% |
Yubo International Biotech Earnings Forecast
Key Yubo International Biotech Financial Ratios
-
The Gross Profit Margin over the past 19 years for YBGJ is 69.32%.
-
The Selling, General & Administrative Expenses for YBGJ have been equal to 183.15% of Gross Profit Margin.
-
The Interest Expense is -7.02% of Operating Income.
-
The Net Earning history of YBGJ is -197.64% of Total Revenues.
-
Per Share Earnings over the last 24 years have been positive in 8 years.
Yubo International Biotech Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | OTCM |
---|---|
Current Symbol: | YBGJ |
Website: | yubogroup.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0.21 |
Quick Ratio: | 0.13 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
YBGJ Technical Analysis vs Fundamental Analysis
Sell
24
Yubo International Biotech (YBGJ)
is a Sell
Is Yubo International Biotech a Buy or a Sell?
-
Yubo International Biotech stock is rated a SellThe current Yubo International Biotech [YBGJ] share price is $0.0461. The Score for YBGJ is 24, which is 52% below its historic median score of 50, and infers higher risk than normal.